Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Brief Behavioral Intervention for Insomnia During Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02165839
Recruitment Status : Completed
First Posted : June 18, 2014
Results First Posted : December 3, 2020
Last Update Posted : December 3, 2020
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Oxana Palesh, Stanford University

Brief Summary:

PRIMARY OBJECTIVE(S):

To evaluate the efficacy of the Brief Behavioral Therapy for Insomnia (BBT-I) in treating insomnia among breast cancer patients receiving chemotherapy.

SECONDARY OBJECTIVE(S):

  • To evaluate the efficacy of the BBT-I in treating cancer-related symptoms such as cancer-related fatigue and cognitive difficulties in breast cancer patients receiving chemotherapy.
  • To examine potential moderators and mediators of BBT-I intervention effects on insomnia, cognitive difficulties, and fatigue. In particular, we are interested in age, depression and anxiety and side effects (hot flashes) as potential moderators of the intervention effects as well as evaluating modifiable behavioral and physiological mechanisms as hypothesized mediators

Condition or disease Intervention/treatment Phase
Breast Cancer Insomnia Behavioral: Brief Behavioral Therapy for Insomnia (BBT-I) Behavioral: Healthy Eating Education Learning (HEAL) Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 139 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Brief Behavioral Intervention for Insomnia During Chemotherapy
Study Start Date : January 2015
Actual Primary Completion Date : June 19, 2019
Actual Study Completion Date : June 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Healthy Eating Education Learning (HEAL)
Control group.
Behavioral: Healthy Eating Education Learning (HEAL)
Experimental: Brief Behavioral Therapy for Insomnia (BBT-I) Behavioral: Brief Behavioral Therapy for Insomnia (BBT-I)



Primary Outcome Measures :
  1. Insomnia Severity Index (ISI) [ Time Frame: 12 months ]

    The effects of the Brief Behavioral Therapy for Insomnia (BBT-I) intervention on insomnia will be measured by the Insomnia Severity Index (ISI). The ISI survey questionnaire is a 7-question survey, with each question having 5 possible answers (none, mild, moderate, severe, or very severe), scored as 0, 1, 2, 3, or 4, respectively. The full range of ISI scores is from 0 to 28. Lower scores are considered good, better, or healthy, and increasingly higher scores are considered to indicate greater insomnia. Clinical interpretation is as follows:

    • 0 to 7 = No clinically significant insomnia
    • 8 to14 = Sub-threshold insomnia (mild)
    • 15 to 21 = Clinical insomnia (moderate severity)
    • 22 to 28 = Clinical insomnia (severe) ISI survey will be conducted at baseline, post intervention, 6 months and 12 months. The outcome is reported as the mean ISI score at baseline; immediately post-intervention (6 weeks nominal); 6 months; and 12 months.


Secondary Outcome Measures :
  1. Brief Fatigue Inventory (BFI) [ Time Frame: 12 months ]

    The Brief Fatigue Inventory (BFI) survey questionnaire is a 9-question survey, with each question having 11 possible answers ("No fatigue" to "As bad as you can imagine"), scored from 0 to 10, with the total score being the sum of a participant's individual questions scores at a timepoint and will range from 0 to 90. Lower scores are considered good, better, or healthy, and increasingly higher scores are considered to indicate greater fatigue.

    The BFI survey was conducted at baseline, post intervention, 6 months, and 12 months. The outcome is reported as the mean of the overall BFI scores with standard deviation at baseline, immediately post-intervention (6 weeks nominal), 6 months, and 12 months.


  2. Clinical Assessment of Depression (CAD) [ Time Frame: 12 months ]

    Anxiety and depression will be assessed by administration of the Clinical Assessment of Depression (CAD). The CAD questionnaire is a 50-item survey, with each statement having 4 possible responses ("Strongly Disagree" to "Strongly Agree"), scored from 1 to 4, The raw scores are then converted to T-scores. A score of 50 represents the mean. A difference of 10 from the mean in either the positive or negative direction indicates a difference of one standard deviation.

    The CAD survey was conducted at baseline, post intervention, 6 months, and 12 months. The outcome is reported as the mean of the overall CAD scores with standard deviation at baseline, immediately post-intervention (6 weeks nominal), 6 months, and 12 months.


  3. Comprehensive Trail Making Test (CTMT) [ Time Frame: At baseline, post intervention, 6 months and 12 months ]

    Neuropsychological assessments will be conducted using the Comprehensive Trail Making Test (CTMT), an assessment of simple attention and executive function, consisting of 5 dot-to-dot exercises that increase with complexity and difficulty. A score of 50 represents the mean. A difference of 10 from the mean in either the positive or negative direction indicates a difference of one standard deviation. Thus, a score of 60 is one standard deviation above the mean, while a score of 30 is two standard deviations below the mean. Overall, higher values indicate better executive functioning, attention, and processing speed.

    The CTMT assessment was conducted at baseline, post intervention, 6 months, and 12 months. The outcome is reported as the mean of the overall CTMT scores with standard deviation at baseline, immediately post-intervention (6 weeks nominal), 6 months, and 12 months.


  4. Hopkins Verbal Learning Test Revised (HVLT-R) Sub-test for Delayed Recall [ Time Frame: At baseline, post intervention, 6 months and 12 months ]

    Neuropsychological assessments will be conducted using the Delayed Recall sub-test from the overall Hopkins Verbal Learning Test Revised (HVLT-R). The result values are known as the T score. A higher T scores indicating better memory (recall).A score of 50 represents the mean. A difference of 10 from the mean in either the positive or negative direction indicates a difference of one standard deviation

    The HVLT-R sub-test assessment for Delayed Recall was conducted at baseline, post intervention, 6 months, and 12 months. The outcome is reported as the mean score with standard deviation at baseline, immediately post-intervention (6 weeks nominal), 6 months, and 12 months.


  5. Hopkins Verbal Learning Test Revised (HVLT-R) Sub-test for Verbal Learning & Memory [ Time Frame: At baseline, post intervention, 6 months and 12 months ]

    Neuropsychological assessments will be conducted using the Verbal Learning and Memory sub-test from the overall Hopkins Verbal Learning Test Revised (HVLT-R). The result values are known as the T score.The higher T scores indicating better memory (recall). A score of 50 represents the mean. A difference of 10 from the mean in either the positive or negative direction indicates a difference of one standard deviation

    The HVLT-R sub-test assessment for Verbal Learning and Memory was conducted at baseline, post intervention, 6 months, and 12 months. The outcome is reported as the mean score with standard deviation at baseline, immediately post-intervention (6 weeks nominal), 6 months, and 12 months.


  6. Controlled Oral Word Association Test (COWAT) [ Time Frame: At baseline, post intervention, 6 months and 12 months ]

    Neuropsychological assessments will be conducted using the Controlled Oral Word Association Test (COWAT), a verbal fluency task that assesses complex cognition. The test value is the the count of words that meet pre-defined criteria within 1 minute, so the minimum is 0 and no fixed maximum exists. Adjustments are made to the raw score based on participant age and education level, resulting in a scaled score. Higher scores reflect a better outcome, meaning better cognition and verbal fluency.

    The COWAT assessment was conducted at baseline, post intervention, 6 months, and 12 months. The outcome is reported as the mean of the COWAT score with standard deviation at baseline, immediately post-intervention (6 weeks nominal), 6 months, and 12 months.


  7. Mobile Cognitive Assessment Battery (MCAB) [ Time Frame: At baseline, post intervention, 6 months and 12 months ]

    Cognitive difficulties will be assessed by administration of the Mobile Cognitive Assessment Battery (MCAB), comprised of 3 neuropsychological tests and a self-reported assessment. MCAB measures cognitive flexibility, accuracy, processing speed, working memory and multitasking.

    The MCAB survey was to be conducted at baseline, post intervention, 6 months, and 12 months. The outcome was to be reported as the mean of the overall MCAB scores with standard deviation at baseline, immediately post-intervention (6 weeks nominal), 6 months, and 12 months.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   adult females ≥ 21 years of age
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA

  • Female
  • Diagnosis of Breast Cancer (Stage I-IIIA)
  • Scheduled for planned cancer treatment (eg, chemotherapy or biologic agents), or treatment is continuing
  • Has ≥ 6 weeks of cancer treatment (eg, chemotherapy or biologic agents) remaining
  • ≥ 21 years of age.
  • Able to understand written and spoken English.
  • Sleep disturbance of 8 or greater on the ISI, and insomnia that began or got worse with diagnosis of cancer or treatment with chemotherapy (to exclude pre-existing, chronic insomnia).
  • Karnofsky score ≥ 70

EXCLUSION CRITERIA

  • Have an unstable self-reported medical or psychiatric illness (Axis I - current or within the last 5 years).
  • Be currently pregnant or nursing
  • History of substance abuse or meet criteria for current alcohol abuse or dependence
  • History (self-reported) of sleep apnea or restless leg syndrome (RLS)
  • Self-report or have a medical record of an unstable comorbid medical or psychiatric condition that would make it unsafe or impossible to adhere to the study protocol
  • Unable or unwilling to discontinue anxiolytics within 4 hours of education sessions
  • Irregular heartbeat or arrhythmia (self-reported or in the medical record)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02165839


Locations
Layout table for location information
United States, California
Stanford University, School of Medicine
Palo Alto, California, United States, 94305
Sponsors and Collaborators
Stanford University
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Oxana Palesh, PhD Stanford University
  Study Documents (Full-Text)

Documents provided by Oxana Palesh, Stanford University:
Informed Consent Form  [PDF] January 31, 2019

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Oxana Palesh, Oxana Palesh PhD, MPH, Stanford University
ClinicalTrials.gov Identifier: NCT02165839    
Other Study ID Numbers: IRB-30470
BRS0042 ( Other Identifier: OnCore )
1R01CA181659-01A1 ( U.S. NIH Grant/Contract )
First Posted: June 18, 2014    Key Record Dates
Results First Posted: December 3, 2020
Last Update Posted: December 3, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Sleep Initiation and Maintenance Disorders
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Nervous System Diseases
Mental Disorders